Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 2,385 trials in your specialties ()
View trials across your selected specialties

Inflammatory Response In Schizophrenia

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Schizophrenia
View Full Trial
INTERVENTION

Drug: Natalizumab, Other: Placebo: normal saline

Eligibility
  • Ages: 18 to 50 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

Brief Summary

Schizophrenia affects a significant proportion of the population and current levels of understanding of the illness is inadequate to treat it effectively. Converging lines of evidence suggest that neuroinflammation occurs in schizophrenia, and specifically over-activity of brain-resident immune cells called microglia. It is however unclear whether activated microglia play a primary role in schizophrenia, or whether this is a secondary phenomenon of no pathophysiological significance. The investigators therefore plan to test the effect of a monoclonal antibody (natalizumab) on psychotic symptoms in a cohort of first episode psychosis patients.

Indocyanine Green for Central Nervous System Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Suspected Central Nervous System Tumors
View Full Trial
INTERVENTION

Drug: Indocyanine Green (ICG), Radiation: intraoperative near-infrared (NIR)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

A specific aim is to determine if Indocyanine Green (ICG) administered pre-operatively, then imaged intraoperatively using our camera will aid in the identification of suspected central nervous system (CNS) tumors. A secondary aim is to understand if the use of ICG during surgery correlates to MR imaging findings including elevated Cho/Cr ratio, rCBV, Ktrans and contrast enhancement.

Breathe Anew for Lung Cancer Survivorship

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Lung Cancer
View Full Trial
INTERVENTION

Combination Product: Breathe Anew Survivorship Program

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Brief Summary

Survivorship programs have become an integral component of modern cancer care programs. In Canada, there has been tremendous success for survivorship programs for breast, prostate, and colorectal cancer, however lung cancer survivorship programs have not been widely developed. The complexity of the disease, high mortality, short survival times, high cost of surveillance, and patient habits have traditionally been barriers against the success of lung cancer survivorship programs. The investigator proposes a feasibility study to pilot a novel intervention titled Breathe Anew, which will aim to identify and overcome the barriers to the design and implementation of a lung cancer survivorship program. The investigator has assembled a multi-disciplinary team of experts and lung cancer survivors who will develop the Breathe Anew survivorship intervention. The intervention will be vetted using an integrated knowledge translation approach, which will involve members of the target population, primarily patients who previously underwent lung resection, to modify the intervention and ensure acceptability. After Breathe Anew has been designed, it will be tested in a pilot study of 50 patients to ensure its feasibility and determine its cost. The ultimate goal of this feasibility study is to lay the groundwork for a subsequent comparative trial to evaluate the impact of Breathe Anew on patient-important outcomes including health related quality and length of life and postoperative complications.

A Clinical Study to Test the Safety, Exposure, and Markers of Efficacy of CSL311 in Patients With Mild Asthma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Asthma
View Full Trial
INTERVENTION

Biological: Human beta common receptor antagonist monoclonal antibody, Drug: Placebo

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Medicines Evaluation Unit, Manchester, United Kingdom

Brief Summary

This is a phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study of CSL311 in patients with mild asthma. The primary objective of this study is to assess the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of CSL311.

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Advanced or Metastatic Solid Tumors
View Full Trial
INTERVENTION

Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States

Brief Summary

To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
View Full Trial
INTERVENTION

Drug: ABT-199, Drug: Rituximab

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Ucsd /Id# 70398, La Jolla, California, United States

Brief Summary

This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study. Subjects who meet criteria for CR, CRi, or MRD-negative PR during the study may discontinue ABT 199. If disease progression occurs, as defined by iwCLL NCI/WG criteria for tumor response, or MRD progression, subjects may re-initiate ABT-199.

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Tumor, Cancer
View Full Trial
INTERVENTION

Drug: AZD6244

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Aurora, Colorado, United States

Brief Summary

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in patients with advanced solid malignancies.

FLYSYN in MRD Positive AML

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Acute Myeloid Leukemia
View Full Trial
INTERVENTION

Biological: FLYSYN

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University Hospital Tuebingen, Tuebingen, Baden-Wuerttemberg, Germany

Brief Summary

This is a first in human, prospective, multicentric, nonrandomized, open-label study to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of the Fc-optimized antibody FLYSYN as monotherapy in adult subjects.

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Non-small Cell Carcinoma
View Full Trial
INTERVENTION

Drug: Binimetinib, Drug: Pembrolizumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.

Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Healthy
View Full Trial
INTERVENTION

Drug: FDG, Dietary Supplement: Ketone Drink, Other: Ketogenetic Diet

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

The purpose of this study is to test different methods of preparation that can be used prior to a test called an FDG PET/CT scan. FDG PET/CT scans are routinely done for evaluation of heart inflammation. Standard preparation for the scan includes a ketogenic (high fat and low carbohydrate) diet for 24 hours and overnight fasting to help suppress the amount of sugar taken up in the heart muscle. However, Investigator still do not know if this preparation is the most effective method. So the Investigator, want to investigate alternative methods for decreasing the amount of sugar uptake seen in the heart during FDG PET/CT scan, thus, investigator will have participants try up to 3 different methods of preparation prior to the FDG PET/CT scans to see which type of preparation works the best.